203 related articles for article (PubMed ID: 34812989)
21. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
[TBL] [Abstract][Full Text] [Related]
23. Utility of copy number variants in the classification of intracranial ependymoma.
Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
25. Expression and Clinical Significance of Translation Regulatory Long Non-Coding RNA 1 (TRERNA1) in Ependymomas.
Malgulwar PB; Nambirajan A; Singh M; Suri V; Sarkar C; Sharma MC
Pathol Oncol Res; 2020 Jul; 26(3):1975-1981. PubMed ID: 31489574
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
27. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
[TBL] [Abstract][Full Text] [Related]
28. The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.
Wang L; Han S; Yan C; Yang Y; Li Z; Yang Z
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1259-1270. PubMed ID: 33387039
[TBL] [Abstract][Full Text] [Related]
29. A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment.
Hashimoto N; Suzuki T; Ishizawa K; Nobusawa S; Yokoo H; Nishikawa R; Yasuda M; Sasaki A
Brain Tumor Pathol; 2023 Jul; 40(3):163-175. PubMed ID: 37322295
[TBL] [Abstract][Full Text] [Related]
30. p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.
Lummus SC; Donson AM; Gowan K; Jones KL; Vibhakar R; Foreman NK; Kleinschmidt-DeMasters BK
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28548702
[TBL] [Abstract][Full Text] [Related]
31. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma.
Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S
Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506
[TBL] [Abstract][Full Text] [Related]
32. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
[TBL] [Abstract][Full Text] [Related]
33. Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.
Benesch M; Mynarek M; Witt H; Warmuth-Metz M; Pietsch T; Bison B; Pfister SM; Pajtler KW; Kool M; Schüller U; Pietschmann K; Juhnke BO; Tippelt S; Fleischhack G; Schmid I; Kramm CM; Vorwerk P; Beilken A; Classen CF; Hernáiz Driever P; Kropshofer G; Imschweiler T; Lemmer A; Kortmann RD; Rutkowski S; von Hoff K
Oncologist; 2019 Sep; 24(9):e921-e929. PubMed ID: 30850560
[TBL] [Abstract][Full Text] [Related]
34. Molecular predictive and prognostic factors in ependymoma.
Benson R; Mallick S; Julka PK; Rath GK
Neurol India; 2016; 64(2):279-86. PubMed ID: 26954807
[TBL] [Abstract][Full Text] [Related]
35. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes.
Senetta R; Miracco C; Lanzafame S; Chiusa L; Caltabiano R; Galia A; Stella G; Cassoni P
Neuro Oncol; 2011 Feb; 13(2):176-83. PubMed ID: 21059755
[TBL] [Abstract][Full Text] [Related]
37. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract][Full Text] [Related]
38. Epithelial-to-mesenchymal transition-related transcription factors are up-regulated in ependymomas and correlate with a poor prognosis.
Malgulwar PB; Nambirajan A; Pathak P; Rajeshwari M; Suri V; Sarkar C; Singh M; Sharma MC
Hum Pathol; 2018 Dec; 82():149-157. PubMed ID: 30067950
[TBL] [Abstract][Full Text] [Related]
39. ZFTA-YAP1 fusion-positive ependymoma can occur in the spinal cord: Letter to the editor.
Lim KY; Lee KH; Phi JH; Yun H; Won JK; Choi SH; Park SH
Brain Pathol; 2022 Jan; 32(1):e13020. PubMed ID: 34506076
[TBL] [Abstract][Full Text] [Related]
40. MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
